Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer ; volume:8 ; number:1 ; day:30 ; month:12 ; year:2008 ; pages:1-5 ; date:12.2008
BMC urology ; 8, Heft 1 (30.12.2008), 1-5, 12.2008
- Creator
-
Ather, M Hammad
- Contributor
-
Abbas, Farhat
Faruqui, Nuzhat
Israr, Mohammad
Pervez, Shahid
SpringerLink (Online service)
- DOI
-
10.1186/1471-2490-8-21
- URN
-
urn:nbn:de:1111-2016071623804
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ather, M Hammad
- Abbas, Farhat
- Faruqui, Nuzhat
- Israr, Mohammad
- Pervez, Shahid
- SpringerLink (Online service)
Other Objects (12)
Neuroendocrine predictors of vasoplegia after cardiopulmonary bypass
Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer
ONECUT2 is a driver of neuroendocrine prostate cancer
Characterization of prostate cancer detected at repeat biopsy
Overdiagnosis and overtreatment of early detected prostate cancer
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression
Predictors of Outcomes in Gastric Neuroendocrine Tumors: A Retrospective Cohort
Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
Loss of EHF facilitates the development of treatment-induced neuroendocrine prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Neuroendocrine predictors of vasoplegia after cardiopulmonary bypass
Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer
ONECUT2 is a driver of neuroendocrine prostate cancer
Characterization of prostate cancer detected at repeat biopsy
Overdiagnosis and overtreatment of early detected prostate cancer
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression
Predictors of Outcomes in Gastric Neuroendocrine Tumors: A Retrospective Cohort
Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
Loss of EHF facilitates the development of treatment-induced neuroendocrine prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Neuroendocrine predictors of vasoplegia after cardiopulmonary bypass
Clinicopathological and immunological profiles of prostate adenocarcinoma and neuroendocrine prostate cancer
ONECUT2 is a driver of neuroendocrine prostate cancer
Characterization of prostate cancer detected at repeat biopsy
Overdiagnosis and overtreatment of early detected prostate cancer
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression
Predictors of Outcomes in Gastric Neuroendocrine Tumors: A Retrospective Cohort
Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
Loss of EHF facilitates the development of treatment-induced neuroendocrine prostate cancer